Results 11 to 20 of about 849 (67)

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis. [PDF]

Int J Cancer
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R.   +30 more
europepmc   +2 more sources

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. [PDF]

Cancer Commun (Lond)
Abstract In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in bladder cancer (BLCA), underscoring its prevalence in both non‐muscle‐invasive and muscle‐invasive forms of the disease. FGFR3 mutations in up to half of BLCAs play a well‐established role in tumorigenesis, shaping distinct tumor initiation patterns ...
Noeraparast M, Krajina K, Pichler R, Niedersüß-Beke D, Shariat SF, Grünwald V, Ahyai S, Pichler M.   +7 more
europepmc   +2 more sources

Current status of precision oncology in adult glioblastoma. [PDF]

Mol Oncol
This review summarizes the current status of precision oncology – targeted therapies based on individual genetic profiles – in glioblastoma. Although some treatments show promise, their applicability and effectiveness remain limited, underlining the need for innovative approaches.
Weller J, Potthoff AL, Zeyen T, Schaub C, Duffy C, Schneider M, Herrlinger U.   +6 more
europepmc   +2 more sources

Heparan Sulfate Chain-Conjugated Laminin-E8 Fragments Advance Paraxial Mesodermal Differentiation Followed by High Myogenic Induction from hiPSCs. [PDF]

Adv Sci (Weinh)
This study describes the new generation laminin fragments, a recombinant form of a laminin E8 fragment conjugated to the heparan sulfate chains. Taking advantage of the new generation laminin fragments, authors established a highly efficient and xeno‐free protocol for paraxial mesoderm differentiation of hiPSCs followed by high myogenic induction ...
Zhao M, Taniguchi Y, Shimono C, Jonouchi T, Cheng Y, Shimizu Y, Nalbandian M, Yamamoto T, Nakagawa M, Sekiguchi K, Sakurai H.   +10 more
europepmc   +2 more sources

Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

Journal of Extracellular Vesicles, Volume 15, Issue 1, January 2026.
Non‐invasive biomarkers are needed to further personalize EGFR tyrosine kinase inhibitor (EGFR TKI) osimertinib treatment in non‐small cell lung cancer (NSCLC) patients. By analysing the proteome of extracellular vesicles (EVs) isolated from an osimertinib resistant NSCLC cell line and from serum of patients given osimertinib in second line within the ...
Albano Cáceres‐Verschae, Petra Hååg, Sofia Joelsson, Per Hydbring, Bo Franzén, Ákos Végvári, Inger Johanne Z. Eide, Nupur Agarwal, Siddharth Sourabh Sahu, Fredrik Stridfeldt, Luigi De Petris, Apurba Dev, Simon Ekman, Odd Terje Brustugun, Rolf Lewensohn, Kristina Viktorsson   +15 more
wiley   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-940, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +3 more sources

Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

Clinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT The pharmacokinetics of regorafenib and its active metabolites, M2 and M5, vary widely among individual patients. However, the relationship between these plasma concentrations and therapeutic efficacy remains unclear. Patients with metastatic colorectal cancer (mCRC) receiving regorafenib as third‐line or later treatment were enrolled.
Kazuo Kobayashi, Takeru Wakatsuki, Erika Sugiyama, Eiji. Shinozaki, Masataka Tajima, Mariko Ogura, Keisho Chin, Akira Ooki, Hiroki Osumi, Shota Fukuoka, Shohei Udagawa, Keitaro Shimozaki, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Wataru Suzuki, Takashi Yokokawa, Hitoshi Sato, Masakazu Yamaguchi, Kensei Yamaguchi   +19 more
wiley   +1 more source

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum

Pediatric Blood &Cancer, Volume 72, Issue 9, September 2025.
ABSTRACT High‐risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger.
Steven G. DuBois, Lucas Moreno, John Anderson, Shahab Asgharzadeh, Ro Bagatell, Maja Beck‐Popovic, Jen Belle, Pablo Berlanga, Nick J. Bird, Louis Chesler, Adam Durbin, Angelika Eggert, Martin Eilers, Sara M. Federico, Matthias Fischer, Susanne A. Gatz, Rani E. George, Sally George, Kelly C. Goldsmith, Juliet Gray, Andras Heczey, Meredith S. Irwin, Leona Knox, Holger N. Lode, Donna Ludwinski, Margaret E. Macy, Robbie G. Majzner, John M. Maris, Shakeel Modak, Jan J. Molenaar, Daniel A. Morgenstern, Yael P. Mossé, Cormac Owens, C. Patrick Reynolds, Claudia Rossig, Gudrun Schleiermacher, Liz Scott, Paul M. Sondel, Frank Speleman, Max van Noesel, Frank Westermann, Judith Wienke, Adam J. Wolpaw, Julie R. Park, Andrew D. J. Pearson   +44 more
wiley   +1 more source

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

Liver International, Volume 45, Issue 9, September 2025.
ABSTRACT Background & Aims Cholangiocarcinoma (CCA) is a rare cancer with limited therapeutic options and a poor prognosis. While first‐line combination therapies have improved outcomes, second‐line treatment remains challenging. Ivosidenib, an IDH1 inhibitor, has shown promise in treating IDH1 mutant CCA, but real‐world data is limited.
Monica Niger, Margherita Rimini, Florian Castet, Anna Melzer, Mario Domenico Rizzato, Tiziana Pressiani, Daniele Lavacchi, Giuseppe Aprile, Torsello Angela, Tiziana Saladino, Noventa Silvia, Pasqua Cito, Alessandro Pastorino, Eduardo Terán‐Brage, Carolina Sciortino, Silvia Camera, Chiara Pircher, Mara Persano, Vincenzo Mazzaferro, Silvia Foti, Kreina Sharela Vega, Thomas J. Ettrich, Lorenzo Antonuzzo, Lorenza Rimassa, Sara Lonardi, Lukas Perkhofer, Teresa Macarulla, Filippo Pietrantonio, Andrea Casadei‐Gardini   +28 more
wiley   +1 more source

Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines

ChemistryOpen, Volume 14, Issue 8, August 2025.
A novel series of hybrid 4‐(4‐benzoylpiperazin‐1‐yl)‐6‐nitroquinoline‐3‐carbonitrile derivatives has been designed, synthetized and evaluated for anticancer properties on the NCI60 panel. Strong antiproliferative effects have been detected against renal cancer cells.
Gabriele La Monica, Alessia Bono, Federica Alamia, Annamaria Martorana, Antonino Lauria   +4 more
wiley   +1 more source